Serelose is prescribed to support the management of two primary health conditions: constipation and portal-systemic encephalopathy (PSE).

Quick Facts

• Supports relief from chronic constipation.
• Assists in the management of portal-systemic encephalopathy (PSE), including the stages of hepatic pre-coma and coma.

Main Uses

For chronic constipation, Serelose is indicated for use in patients who have not achieved relief from initial dietary changes or increased fiber intake. It works to promote a more frequent and softer consistency of stool, contributing to regularity for individuals with a history of long-lasting constipation.

In the setting of liver disease, Serelose is utilized to assist in the prevention and treatment of portal-systemic encephalopathy, a condition that can affect brain function. Treatment aims to reduce the presence of ammonia in the blood, which may contribute to improved mental status for patients experiencing this condition.

Patients should consult with a healthcare professional to determine if Serelose is an appropriate option for their individual needs.

Eligibility Map: Who can and cannot use Serelose — Official Regulatory Information

The following information is based strictly on governmental regulatory documents that define the official eligibility profile for Serelose (Lactulose).

Category	Official Regulatory Statement
Populations for whom use is contraindicated:	Patients with Galactosaemia (a rare genetic disorder) or who require a low galactose diet, gastrointestinal obstruction, digestive perforation or risk thereof, and acute inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) [1.1, 2.7].
Age-related eligibility rules:	Approved for adults for both main indications. Use in infants and small children is considered exceptional and requires medical supervision [1.1]. Safety and effectiveness have not been established in pediatric patients for the treatment of Hepatic Encephalopathy (PSE) [1.5, 2.6].
Condition-specific eligibility rules:	Use with caution in patients with Diabetes Mellitus due to the presence of small amounts of unabsorbed sugars [1.2, 3.1]. Older adults on long-term treatment (over six months) require periodic serum electrolyte monitoring [1.2, 3.1].
Pregnancy and lactation eligibility status:	Pregnancy: May be used if clearly needed, as systemic absorption is negligible [1.2, 2.6]. Lactation: Use is generally allowed, though regulatory bodies advise caution [1.2, 2.5].

Official Eligibility Statements:

• Use is contraindicated in patients with severe gastrointestinal conditions or those with the metabolic disorder Galactosaemia [1.1, 2.7].
• Safety and effectiveness have not been established for PSE treatment in pediatric patients [1.5, 2.6].
• Caution is advised for patients with Diabetes Mellitus or lactose intolerance [1.2, 2.7].

Connection to the overall eligibility profile: The official regulatory documents strictly define eligibility based on absolute prohibitions related to intestinal integrity and sugar intolerance, alongside specific cautions for chronic use in older adults and patients with metabolic issues. The profile also clearly notes where data are not established, particularly for pediatric populations, preventing use in the absence of documented regulatory support.

Serelose Interactions with other medicines and products

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Potassium-losing medicines (e.g., diuretics, corticosteroids), Cardiac glycosides, Intestinal anti-infective agents, Non-absorbable antacids, Other laxatives.
Specific interacting medicines (if explicitly listed)	Thiazides, Steroids, Amphotericin B, Neomycin.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (electrolyte balance), Local efficacy interference (colonic pH alteration, bacterial flora depletion).
Timing-based interaction rules (if applicable)	Co-administration of other laxatives is generally avoided when Serelose is prescribed for Portal-Systemic Encephalopathy (PSE).

---

Interaction Classifications (High-Level)

Classification	Regulatory Status / Context
Interaction severity classification (as defined in official documents)	Clinically significant risk (Electrolyte-modulating drugs); Efficacy-reducing interaction (Colonic environment modifiers).
Regulatory basis (EMA / FDA / etc.)	Based on official Prescribing Information and SmPC-aligned documentation.
Interaction-context constraints (as defined in official documents)	Efficacy interactions are specifically relevant to the management of Portal-Systemic Encephalopathy (PSE).

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with potassium-losing medicines (such as Thiazides) may increase the loss of potassium from the body.
• The use of cardiac glycosides concurrently can lead to an increased effect of the glycosides due to the potential for potassium deficiency.
• Intestinal anti-infective agents (like Neomycin) may decrease the therapeutic efficacy of Serelose by disrupting the necessary bacterial degradation of the active compound.
• Non-absorbable antacids may inhibit the reduction in colonic pH, which can reduce its effectiveness when treating PSE.
• The use of other laxatives is generally avoided during initial PSE therapy to prevent the false suggestion of an adequate therapeutic response.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is structured around two key concepts: the pharmacodynamic risk associated with electrolyte imbalance and the local efficacy interference in the colon. The official documentation details how other medicines can worsen potassium loss or reduce the intended colonic acidification. A procedural constraint is also mandated to avoid co-administering other laxatives during PSE therapy.

The mechanism of action for Serelose (Lactulose) is peripheral and relies on a dual process localized entirely within the large intestine, resulting in physicochemical and motility-modulating effects.

---

Colonic Osmotic Action and Fluid Dynamics

This core mechanism is driven by the fact that the Lactulose molecule resists hydrolysis by human enzymes, reaching the colon intact. Acting as an osmotic agent, the molecule and its metabolites create a hypertonic environment, actively drawing water into the lumen from the surrounding tissues. This increases the turgor and volume of the colonic contents, resulting in increased fecal hydration and mass.

---

Microbiota Fermentation and Propulsive Modulation

In the colon, the drug becomes a metabolic substrate for saccharolytic bacteria (e.g., Bifidobacterium), which break it down into low-molecular-weight organic acids, such as lactic and acetic acids. These acids significantly lower the intraluminal pH and act as chemical signals that physically and chemically stimulate the colon wall, influencing peristaltic activity and modifying colonic transit rate.

---

pH-Dependent Nitrogenous Waste Trapping

A vital consequence of the acidification mechanism is its impact on nitrogenous waste. The reduced pH promotes the conversion of free ammonia (, NH3), a highly absorbable neurotoxin, into the non-absorbable ammonium ion (, NH4^+). This process of ion trapping significantly reduces the entry of , NH3 into the systemic circulation, thereby modulating the flux of , NH3 into the systemic circulation.

How to Use Serelose

Serelose (Lactulose) administration follows defined parameters regarding the route, dose range, and necessary adjustment protocol. The medicine is primarily available as an oral solution or a powder for solution. The oral solution may be administered undiluted or mixed with liquids such as water, fruit juice, or milk to improve acceptability.

---

Official Dosing and Administration Patterns

Feature	Guideline
Route of Administration	Primarily Oral. Rectal administration (enema) is an approved method for acute phases of Portal-Systemic Encephalopathy (PSE).
Dosing for Constipation (Adult)	Initial doses range from 15 mL to 30 mL (10 g to 20 g) taken once daily, which may be increased to a maximum of 60 mL (40 g) daily if necessary.
Dosing for PSE (Adult)	Initial oral loading doses are 30 mL to 45 mL (20 g to 30 g) hourly until a laxative effect is achieved. The rectal enema requires mixing 300 mL of solution with 700 mL of water or normal saline, retained for 30 to 60 minutes.
Dosing Frequency	For constipation, the dose is typically taken once daily or in two divided doses, ideally at the same time each day (e.g., during breakfast).

---

Procedural and Titration Rules

The most critical procedural constraint is the titration requirement: the dosage for both indications must be adjusted every one to two days to achieve a goal of two to three soft stools daily. The desired effect for constipation may take 24 to 48 hours to manifest, indicating a typical slow onset of action. Throughout the course of treatment, patients are advised to maintain adequate fluid intake, generally 1.5 to 2 liters per day. While no specific dose adjustments are typically required for older adults or patients with renal or hepatic impairment, pediatric dosing for constipation is typically determined based on body weight and age.

Research Evidence / Overview of Studies

Early-stage research was conducted to understand the biological activity of Serelose and to identify a safe dosing range. These studies established the pharmacokinetic and pharmacodynamic profiles of the compound, confirming its minimal absorption in the small intestine and subsequent metabolism by colonic bacteria.

---

Phase 3 Trials: Efficacy and Long-Term Outcomes

Phase 3 trials focused on evaluating the potential association between Serelose use and outcomes in individuals with chronic constipation and portal-systemic encephalopathy (PSE).

• Symptom Markers: Research has evaluated whether Serelose is associated with an increase in the number of bowel movements and an improvement in stool consistency. In studies focused on chronic constipation, the onset of a change in bowel habit was typically noted between 24 and 48 hours after administration.
• Portal-Systemic Encephalopathy (PSE): In studies of PSE, the use of Serelose was associated with a decrease in blood ammonia levels. This effect is thought to be related to the acidic environment created in the colon, which assists in the removal of ammonia from the body.

---

Adverse Events and Tolerability Data

Research collected data regarding adverse events and tolerability across all phases of clinical development.

• Common Adverse Events (AEs): In clinical studies, the most frequently reported adverse events included mild gastrointestinal symptoms, such as flatulence, bloating, abdominal discomfort, and cramping. These effects were typically transient, particularly upon initiation of treatment. Diarrhea was the most significant dose-dependent adverse effect.
• Specific Patient Groups: Data regarding adverse events has been collected for the treatment in adult populations. Research explored the potential for complications in individuals with specific underlying conditions, such as those with galactosemia or intestinal obstruction.

Key Studies & References

1. Lactulose - StatPearls - NCBI Bookshelf (NIH)
2. Label: LACTULOSE solution - DailyMed (FDA-associated label information)

Common questions about Serelose (FAQ)

Q: Can Serelose be taken with food, or should it be taken on an empty stomach?

The official product information does not strictly specify whether Serelose must be taken with or without food. The labeling mentions that the solution may be mixed with liquids, such as water, milk, or fruit juice. Dosing frequency is generally once or twice daily, sometimes scheduled around mealtimes like breakfast.

Q: What are the signs of an overdose on Serelose?

According to official product labeling, the main signs expected in the event of taking too much Serelose are severe diarrhea and abdominal cramps. Excessive use may also lead to fluid loss and issues with electrolyte balance, specifically a potential risk of low potassium levels.

Q: Can I use Serelose if I have a history of kidney problems?

Regulatory documents indicate that no specific dosage adjustment is typically required for patients with renal (kidney) impairment when Serelose is used for constipation. However, if treatment continues long-term, official information suggests that blood salt levels, known as serum electrolytes, should be checked periodically.

Q: What is the specific dosage of Serelose for infants or pediatric patients with constipation?

Official regulatory documents acknowledge the use of Serelose for constipation in infants and children when determined by a healthcare provider. The regulatory documents provide initial dose ranges, and the dose is adjusted by a healthcare provider based on the clinical response. If diarrhea occurs, the product labeling notes that a dose reduction is typically necessary.

Q: Is Serelose safe to take every day, or is it only for short-term use?

Official labeling confirms that Serelose is used for long-term management of chronic conditions, such as Portal-Systemic Encephalopathy (PSE). For any continuous use extending beyond six months, particularly in older or debilitated patients, official safety guidance recommends regular monitoring of serum electrolytes (blood salt levels).

Q: Is Serelose effective for treating all types of constipation?

Official labeling states the indication for Serelose is the treatment of constipation. The effectiveness has been documented in individuals who experience chronic constipation. The regulatory information does not detail its use or comparison across every single type of constipation.

Storage Conditions and Stability

Serelose (Lactulose solution) must be stored at controlled room temperature, typically 20 C to 25 C. Official labeling mandates that the product not be frozen or refrigerated and must be protected from prolonged direct light exposure. The container should be kept tightly closed to maintain product integrity.

A normal darkening of color may occur but does not affect the medicine's action. However, the product must not be used if extreme darkening or turbidity develops from excessive heat or light. For some formulations, the product is stable for up to 12 months after first opening.

Child Safety and Disposal

It is an explicit regulatory requirement that Serelose be kept out of the sight and reach of children and dispensed with a child-resistant closure. Disposal of unused or expired medicine must be done in accordance with local regulations and should not be discarded via wastewater or standard household waste.